A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy

Clinical Neurosurgery

Volumn 56, Issue , 2009, Pages 107-118

  Ng, Kimberly ^a   Nitta, Masayuki ^a   Lauren, Hu ^a   Kesari, Santosh ^a   Kung, Andrew ^a   D'Andrea, Alan ^a   Chen, Clark C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CESIUM 137; LACTACYSTIN; LUCIFERIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA; TEMOZOLOMIDE; ALKYLATING AGENT; BORONIC ACID DERIVATIVE; DACARBAZINE; DRUG DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSMA 1 GENE; RADIOSENSITIZATION; RNA INTERFERENCE; SENSITIZATION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CULTURE TECHNIQUE; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BORONIC ACIDS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; DACARBAZINE; GLIOBLASTOMA; HUMANS; MICE; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 77952312620     PISSN: 00694827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Aghi M, Rabkin S, Martuza RL: Effect of chemotherapy-induced DNA repair oncolytic herpes simplex viral replication. J Natl Cancer Inst 98:38-50, 2006.
2. Amador V, Ge S, Santamaria PG, Guardavaccaro D, Pagano M: APC/ C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 27:462-473, 2007.
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
4. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ: Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28: 8189-8198, 2008.
5. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-2734, 2002.
6. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B: PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58:410-419, 2004.
7. Chen CC, Taniguchi T, D'Andrea A: The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med 85: 497-509, 2007.
8. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS: Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4:1364-1368, 2005.
9. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681, 2006.
10. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21, 1994.
11. Consortium International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature 431: 931-945, 2004.
12. Curtin NJ: PARP inhibitors for cancer therapy. Expert Rev Mol Med 7(4):1-20, 2005.
13. Darkes MJM, Plosker GL, Jarvis B: Temozolomide: A review of its use in the treatment of malignant gliomas, malignant melanoma, and other advanced cancers. Am J Cancer 1:55-80, 2002.
14. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051, 1994.
15. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD: p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68:10034-10039, 2008.
16. Elenich LA, Nandi D, Kent AE, McCluskey TS, Cruz M, Iyer MN, Woodward EC, Conn CW, Ochoa AL, Ginsburg DB, Monaco JJ: The complete primary structure of mouse 20S proteasomes. Immunogenetics 49:835-842, 1999.
17. Friedberg EC, Graham WC, Siede W (eds): DNA Repair and Mutagenesis. Washington, DC, American Society for Microbiology, 1995, pp 1- 47.
18. Hannon GJ, Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 431:371-378, 2004.
19. Harrison JC, Haber JE: Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet 40:209-235, 2006.
20. Henninger N, Sicard KM, Bouley J, Fisher M, Stagliano NE: The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 398:300-305, 2006.
21. Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849, 2001.
22. Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963, 2001.
23. Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G, Selzer E, Verheij M, Hendry JH: Tumor radiosensitizers-Current status of development of various approaches: Report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 64: 551-561, 2006.
24. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070-1077, 1995.
25. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479, 1999.
26. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD: Fanconi anemia pathway- deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117:1440-1449, 2007.
27. Laurent N, de Boüard S, Guillamo JS, Christov C, Zini R, Jouault H, Andre P, Lotteau V, Peschanski M: Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3:129-136, 2004.
28. Legnani FG, Pradilla G, Thai QA, Fiorindi A, Recinos PF, Tyler BM, Gaini SM, DiMeco F, Brem H, Olivi A: Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol 77:225-232, 2006.
29. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH: Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53:503-517, 2007.
30. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15:1311-1333, 2001.
31. Maupin-Furlow JA, Humbard MA, Kirkland PA, Li W, Reuter CJ, Wright AJ, Zhou G: Proteasomes from structure to function: Perspectives from Archaea. Curr Top Dev Biol 75:125-169, 2006.
32. Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J, Reed E, Neckers L: Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 60:1343-1354, 2000.
33. Mischel PS, Cloughesy TF: Targeted molecular therapy of GBM. Brain Pathol 13:52-61, 2003.
34. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380, 2003.
35. Morris KV: RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbiol Immunol 320:211-224, 2008.
36. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U SA 91:7727-7731, 1994.
37. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y, Saya H: Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 23:6548-6558, 2004.
38. Pagano M: Control of DNA synthesis and mitosis by the Skp2-p27- Cdk1/2 axis. Mol Cell 14:414-416, 2004.
39. Pédeboscq S, L'Azou B, Passagne I, De Giorgi F, Ichas F, Pometan JP, Cambar J: Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol 7:99-111, 2008.
40. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005.
41. Reardon DA, Rich JN, Friedman HS, Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253-1265, 2006.
42. Richardson PG, Mitsiades C, Hideshima T, Anderson KC: Bortezomib: Proteasome. Inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47, 2006. (Pubitemid 43261977)
43. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100:13513-13518, 2003.
44. Rubin LL, Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 22:11-28, 1999.
45. Runge VM: Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12:205-213, 2000.
46. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810, 1997.
47. Sherwood SW, Kung AL, Roitelman J, Simoni RD, Schimke RT: In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N- acetylleucylleucylnorleucinal. Proc Natl Acad Sci USA 90:3353-3357, 1993.
48. Shi Q, King RW: Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437:1038-1042, 2005.
49. Shrivastav M, De Haro LP, Nickoloff JA: Regulation of DNA double- strand break repair pathway choice. Cell Res 18:134-147, 2008.
50. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004.
51. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, Jiricny J: Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 18:1331-1344, 2004.
52. Stupp R, van den Bent MJ, Hegi ME: Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206, 2005.
53. Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M, Wysocki M: Activity of bortezomib in glioblastoma. Anticancer Res 26:4499-4503, 2006.
54. Voorhees PM, Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46:189-213, 2006.
55. Warnke PC, Timmer J, Ostertag CB, Kopitzki K: Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol 57:136-139, 2005.
56. Weaver BA, Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7-12, 2005.
57. Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, Labutti J, Mazzola AM, Patil AD, Reimer CL, Solomon MS, Stirling M, Tian Y, Tsu CA, Weatherhead GS, Zhang JX, Rolfe M: Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 5:3052-3061, 2006.
58. Wolf F, Wandke C, Isenberg N, Geley S: Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J 25:2802-2813, 2006.
59. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS: Convection-enhanced delivery ofa topoisom- erase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol 9:20-28, 2007.
60. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24:344-354, 2005.
61. Zhou G, Kowalczyk D, Humbard MA, Rohatgi S, Maupin-Furlow JA: Proteasomal components required for cell growth and stress responses in the Haloarchaeon haloferax volcanii. J Bacteriol 190:8096-8105, 2008.
62. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL: Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 118:3109-3122, 2008.